Baxter and Dorizoe Agree to Develop More Than 20 Generic Injectables

June 15, 2017

The companies announced an agreement where Dorizoe will work with Baxter to develop more than 20 generic injectable products.

On June 14, 2017, Baxter International announced that it has entered into an agreement with Dorizoe Lifesciences Limited a global contract research and development organization, that will facilitate accelerated development of more than 20 generic injectable products-including anti-infectives, oncolytics, and cardiovascular medicines. According to a press release from Baxter, Dorizoe will work with the company to perform certain product development activities, and Baxter will hold worldwide manufacturing and commercialization rights. Financial terms of the agreement were not disclosed.

Baxter produces difficult-to-manufacture oncology drugs and standard-dose, ready-to-use premixed injectable products. According to the companies, this agreement will build upon Dorizoe’s R&D capabilities and Baxter’s differentiated technologies, advanced manufacturing, and global marketing and hospital channel presence to help accelerate the introduction of Baxter’s generic molecules into the market.

Source: Baxter